Prostate cancer is caused by cells growing uncontrollably in the prostate, a gland in the male reproductive system located under the bladder. 99% of prostate cancers occur in men over the age of 50. Although monitoring has improved detection, it has had little effect on survival rates.
The Prostate Cancer GeCIP domain will study the DNA of patients recruited to 100,000 Genomes Project. Their aim is to uncover what changes (mutations) take place in the DNA of normal prostate that cause them to become cancerous. They hope to link these mutations to how severe the tumour becomes, and whether or not it reacts to treatment.
In the future, the hope is that by understanding each individual patient’s prostate tumour and its DNA mutations, a patient’s treatment can be tailored to better suit their particular type of cancer. They also hope to use this opportunity to develop drugs, or repurpose existing ones, that are specific to certain genetic types of prostate cancer.